Azenta has been granted a patent for a method to discover specific functional antibodies. The method involves analyzing the sequence composition and frequency of variable regions of immune host antibodies. It allows for quick and accurate identification of antibody sequences, improving the efficiency of obtaining specific functional antibodies. The patent also includes a method for identifying influenza virus recombinant antibodies using high-throughput sequencing and affinity testing. GlobalData’s report on Azenta gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Azenta, Semiconductor fabrication robots was a key innovation area identified from patents. Azenta's grant share as of September 2023 was 58%. Grant share is based on the ratio of number of grants to total number of patents.
Method for identifying influenza virus recombinant antibodies
A recently granted patent (Publication Number: US11773510B2) describes a method for identifying a recombinant antibody for the influenza virus. The method involves several steps, including extracting total RNA from an immunized host and constructing an antibody sequence library. High-throughput sequencing is then performed to obtain the sequences of the antibody variable region genes for the target antigen. The method further involves selecting specific homologous clusters of heavy chain CDR3 and light chain CDR3. The full-length amino acid sequences of the highest frequency antibody variable regions containing these homology clusters are identified as candidate sequences. The nucleic acid sequences of these candidate sequences are determined and expressed in vitro to produce a candidate influenza virus recombinant antibody. The affinity of the candidate antibody to the antigen is then tested to determine its functionality.
The patent also includes additional claims related to the method. These claims specify that the antibody sequence library can be generated using RACE (Rapid Amplification of cDNA Ends) and/or RT (Reverse Transcription) library construction methods. The host for the immunization can be a mammal, amphibian, fish, bird, or combinations thereof. The RACE library construction can include a PCR amplicon library construction method. High-throughput sequencing can be performed using various techniques such as sequencing by synthesis, sequencing by joining, sequencing by hybridization, single molecule DNA sequencing, multiple polymerase community sequencing, or nano-pore sequencing. The patent also specifies that the total RNA can be extracted from various sources, including peripheral blood, lymphoid organs, spleen, bone marrow, liver, memory B cells, plasma cells, or plasmablasts.
Overall, this patent describes a method for identifying a recombinant antibody for the influenza virus using high-throughput sequencing and specific selection of homologous clusters. The method provides a way to generate candidate antibodies with potential therapeutic applications for influenza.
To know more about GlobalData’s detailed insights on Azenta, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
